What is DBV Technologies Return-on-Tangible-Asset?
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. DBV Technologies's annualizedNet Income for the quarter that ended in Dec. 2023 was $-44.74 Mil. DBV Technologies's average total tangible assets for the quarter that ended in Dec. 2023 was $186.33 Mil. Therefore, DBV Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -24.01%.
The historical rank and industry rank for DBV Technologies's Return-on-Tangible-Asset or its related term are showing as below:
DBVT'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -94.67 Med: -49.55 Max: -19.16
Current: -33.88
During the past 13 years, DBV Technologies's highest Return-on-Tangible-Asset was -19.16%. The lowest was -94.67%. And the median was -49.55%.
DBVT's Return-on-Tangible-Asset is ranked better than 54.63% of 1556
companies
in the Biotechnology industry
Industry Median: -40.17
vs DBVT: -33.88
DBV Technologies Return-on-Tangible-Asset Historical Data
The historical data trend for DBV Technologies's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DBV Technologies's Return-on-Tangible-Asset
For the Biotechnology subindustry, DBV Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DBV Technologies's Return-on-Tangible-Asset Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DBV Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where DBV Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
DBV Technologies Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of DBV Technologies's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
DBV Technologies (DBV Technologies) Business Description
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DBVT has been successfully added to your 